Filtered By:
Specialty: Cardiology
Drug: Aspirin
This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 932 results found since Jan 2013.
High-on-Aspirin Platelet Reactivity Differs Between Recurrent Ischemic Stroke Associated With Extracranial and Intracranial Atherosclerosis
CONCLUSIONS: Recurrent stroke due to ECAS was more strongly associated with HAPR and insufficient antiplatelet inhibition than was that due to ICAS. Artery-to-artery embolism was associated with HAPR in recurrent ischemic stroke as a result of ICAS or ECAS.PMID:35796267 | DOI:10.3988/jcn.2022.18.4.421
Source: Atherosclerosis - July 7, 2022 Category: Cardiology Authors: Kyung Chul Noh Hye-Yeon Choi Ho Geol Woo Jun Young Chang Sung Hyuk Heo Dae-Il Chang Bum Joon Kim Source Type: research
P2Y12 Inhibitors versus Aspirin Monotherapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Disease Events: A Systematic Review and Meta-analysis
CONCLUSION: Use of P2Y12 inhibitor monotherapy is associated with lower rates of myocardial infarction and stroke in ASCVD patients without any significant difference in mortality, or bleeding compared to aspirin monotherapy.PMID:35764143 | DOI:10.1016/j.cpcardiol.2022.101292
Source: Atherosclerosis - June 28, 2022 Category: Cardiology Authors: Ahmad Al-Abdouh Waiel Abusnina Mohammed Mhanna Qais Radideh Hossam Alzu Anan Abu Rmilah Ahmad Jabri Mahmoud Barbarawi Khaldun Obeidat Taqwa Alabduh Erin D Michos Talal Alnabelsi Timir K Paul Source Type: research
Prognostic performance of GRACE and TIMI risk scores in critically ill patients with sepsis and a concomitant myocardial infarction
CONCLUSIONS: GRACE and TIMI scores did not predict in-hospital severe ischaemic events and mortality in patients with AMI during sepsis. Among individual components of both scores, previous aspirin use was associated with poor prognosis. However, because of lack of statistical power, we cannot formally rule out the usefulness of these scores in this setting.PMID:35710774 | DOI:10.1016/j.acvd.2022.03.007
Source: Archives of Cardiovascular Diseases - June 17, 2022 Category: Cardiology Authors: Cyrielle Desnos St éphane Ederhy Pierre Belnou Nathana ël Lapidus Guillaume Lefevre Guillaume Voiriot Ariel Cohen Muriel Fartoukh Vincent Labb é Source Type: research
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review
CONCLUSIONS AND RELEVANCE: Dose adjustment and low-intensity treatment are 2 different forms of dose-reduced DOACs. Dose adjustment is mostly relevant for AF and should be done based on the approved criteria. Dose adjustment of DOACs should not be used for acute VTE treatment in most cases. In contrast, low-intensity DOACs may be used for primary or secondary VTE prevention for studied and approved indications. Attention should be given to routine practice patterns to align the daily clinical practice with existing evidence of safety and efficacy.PMID:35648414 | DOI:10.1001/jamacardio.2022.1292
Source: Atherosclerosis - June 1, 2022 Category: Cardiology Authors: Behnood Bikdeli Farbod Zahedi Tajrishi Parham Sadeghipour Azita H Talasaz John Fanikos Giuseppe Lippi Deborah M Siegal John W Eikelboom Manuel Monreal David Jimenez Jean M Connors Walter Ageno Geoffrey D Barnes Gregory Piazza Dominick J Angiolillo Sahil A Source Type: research
Apolipoprotein E* Ɛ2 carriers exhibit high aspirin-treated platelet reactivity and low cardiovascular risk during long-term aspirin treatment
CONCLUSIONS: Our results demonstrated that APOE*Ɛ2 carriers can derive additional CV benefit from long-term aspirin treatment. Moreover, it was observed that APOE2 interacts with cyclooxygenase-1 (COX-1) and upregulates its activity. The CV-protective effect of aspirin in Ɛ2 carriers is likely attributed to APOE2 upregulating vascular COX-1-mediated CV protective pathway, together with aspirin partially inhibiting platelet COX-1-mediated platelet aggregation.PMID:35647761 | DOI:10.1093/ageing/afac119
Source: Atherosclerosis - June 1, 2022 Category: Cardiology Authors: Xiao-Li Li Qiang Wang Guo-Dong Jia Hui-Jun Yin Yao-Hui Wang Chao Hu Xiao-Qing Wang Yang Yang Source Type: research
Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis
ConclusionThe current study demonstrated that the cardiovascular benefits of low-dose aspirin were equally balanced by major bleeding events. In addition, the potential beneficial effects might be seen in the population ≤ 70 years of age with high cardiovascular risk and no increased risk of bleeding.
Source: American Journal of Cardiovascular Drugs - May 16, 2022 Category: Cardiology Source Type: research
True Efficacy of LAA Closure: Patient Outcomes on Long-term Single-Antiplatelet or No Therapy: Insights From the EWOLUTION Registry
CONCLUSIONS: Outcome data of patients on SAPT/no therapy for ≥1 year following Watchman implantation in the EWOLUTION registry suggest the efficacy and safety of LAAO.PMID:35501111
Source: The Journal of Invasive Cardiology - May 2, 2022 Category: Cardiology Authors: Christina Paitazoglou Martin W Bergmann H üseyin Ince Stephan Kische Aleksandr Romanov Thomas Schmitz Boris Schmidt Tommaso Gori Felix Meincke Alexey Vladimir Protopopov Timothy Betts Elisa Vireca Peter Wohlmuth Lucas Boersma the
EWOLUTION Investigators Source Type: research
Potential role for pentoxifylline as an anti-inflammatory drug for patients with acute coronary syndrome
Exp Ther Med. 2022 Jun;23(6):378. doi: 10.3892/etm.2022.11305. Epub 2022 Apr 8.ABSTRACTThe link between inflammation and acute coronary syndrome (ACS) remains to be sufficiently elucidated. It has been previously suggested that there is an inflammatory process associated with ACS. Pentoxifylline, a methylxanthine derivate, is known to delay the progression of atherosclerosis and reduce the risk of vascular events, especially by modulating the systemic inflammatory response. The present study is a single-blind, randomized, prospective study of pentoxifylline 400 mg three times a day (TID) added to standard therapy vs. stand...
Source: Atherosclerosis - May 2, 2022 Category: Cardiology Authors: Daniel Miron Brie Cristian Mornos Diduta Alina Brie Constantin Tudor Luca Lucian Petrescu Madalina Boruga Source Type: research
